Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.9K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.6K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.6K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Distribution, severity, and management of joint pain in patients with acromegaly.

European journal of endocrinology·2026
Same author

Management of endocrine disease: update on the management of pituitary apoplexy.

European journal of endocrinology·2026
Same author

Approach to the Patient with Cushing's Syndrome: Use of Anticoagulation Therapy.

The Journal of clinical endocrinology and metabolism·2025
Same author

Patient perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society international patient survey.

Pituitary·2025
Same author

EndoCompass Project: Research Roadmap for Pituitary and Neuroendocrine Tumor Endocrinology.

Hormone research in paediatrics·2025
Same journal

Control of muscle mass and accretion.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Multiple endocrine neoplasia type 2: From molecular genetics to precision therapy.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Nutritional advice for patients with obesity and prediabetes.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Effects of prolonged physical training on skeletal muscle mass accrual throughout the life span.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Type 2 diabetes and obesity in South Asian patients with polyendocrine metabolic ovarian syndrome: The emerging role of metabolomics.

Best practice & research. Clinical endocrinology & metabolism·2026
Same journal

Stress and the interaction of the hypothalamic-pituitary-adrenal axis with other pituitary axes and its consequences on muscle mass.

Best practice & research. Clinical endocrinology & metabolism·2026
See all related articles

Related Experiment Video

Updated: Apr 27, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K

Impulse control disorders and dopamine agonists.

Ross Hamblin1, Georgia Ntali2, Niki Karavitaki2

  • 1Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom; Department of Endocrinology and Diabetes, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.

Best Practice & Research. Clinical Endocrinology & Metabolism
|April 25, 2026
PubMed
Summary
This summary is machine-generated.

Dopamine agonists (DAs) may increase impulse control disorder (ICD) risk in prolactinoma patients. This review examines DA-associated ICD prevalence, variability, and clinical management strategies for pituitary tumor patients.

Keywords:
Dopamine agonistImpulse control disorderPituitary tumourProlactinoma

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

8.3K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Related Experiment Videos

Last Updated: Apr 27, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

8.3K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Area of Science:

  • Neuroendocrinology
  • Behavioral Science

Background:

  • Impulse control disorders (ICDs) are linked to dopamine agonist (DA) medications.
  • DAs are frequently prescribed for prolactinoma, a common pituitary tumor.

Purpose of the Study:

  • To review the prevalence of ICDs in pituitary tumor patients.
  • To evaluate the association between DAs and ICDs.
  • To outline clinical management and identify research gaps.

Main Methods:

  • Narrative review of existing literature.
  • Analysis of studies on ICD prevalence in pituitary tumor patients.
  • Appraisal of evidence linking DAs to ICDs.

Main Results:

  • Significant association noted between DA use and ICDs.
  • Variability in reported ICD prevalence exists.
  • Evidence supports a link, but further research is needed.

Conclusions:

  • DA treatment for prolactinoma may elevate ICD risk.
  • Clinical vigilance and further research are crucial for managing DA-associated ICDs.